Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dasatinib-induced lupus.
Rea D, Bergeron A, Fieschi C, Bengoufa D, Oksenhendler E, Dombret H. Rea D, et al. Among authors: dombret h. Lancet. 2008 Aug 30;372(9640):713-4. doi: 10.1016/S0140-6736(08)61295-7. Lancet. 2008. PMID: 18761212 No abstract available.
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia.
Rea D, Raffoux E, Cayuela JM, Maarek O, Dombret H. Rea D, et al. Among authors: dombret h. Leukemia. 2009 Jun;23(6):1158-9. doi: 10.1038/leu.2008.376. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151779 No abstract available.
A new pattern of cytosine-arabinoside-induced lung toxicity.
Chagnon K, Boissel N, Raffoux E, Dombret H, Tazi A, Bergeron A. Chagnon K, et al. Among authors: dombret h. Br J Haematol. 2009 Dec;147(5):771-4. doi: 10.1111/j.1365-2141.2009.07895.x. Epub 2009 Sep 4. Br J Haematol. 2009. PMID: 19735260 Free article. No abstract available.
Severe peripheral arterial disease during nilotinib therapy.
Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dörken B, Valent P. Le Coutre P, et al. Among authors: dombret h. J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8. doi: 10.1093/jnci/djr292. Epub 2011 Aug 2. J Natl Cancer Inst. 2011. PMID: 21813414 No abstract available.
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
Coude MM, Luycx O, Cariou ME, Maarek O, Dombret H, Cayuela JM, Rea D. Coude MM, et al. Among authors: dombret h. Br J Haematol. 2012 May;157(3):407-10. doi: 10.1111/j.1365-2141.2011.09016.x. Epub 2012 Jan 9. Br J Haematol. 2012. PMID: 22225474 Free article. No abstract available.
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Cluzeau T, Lippert E, Cayuela JM, Maarek O, Migeon M, Noguera ME, Dombret H, Rea D. Cluzeau T, et al. Among authors: dombret h. Eur J Haematol. 2015 Nov;95(5):480-3. doi: 10.1111/ejh.12576. Epub 2015 May 20. Eur J Haematol. 2015. PMID: 25941032
448 results